Importantly, this benefit appears to be a class effect, meaning that it is observed across different SGLT2 inhibitors and is particularly pronounced in patients with established cardiovascular disease or multiple risk factors, including heart failure and chronic kidney disease [4,24,25]. The gene discussed is SLC5A2; the disease is chronic kidney disease.